Versant Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$15.4K Buy
534
+40
+8% +$982 ﹤0.01% 2083
2026
Q2
$10.6K Hold
494
– – ﹤0.01% 2212
2026
Q1
$6.86K Sell
494
-116
-19% -$1.85K ﹤0.01% 2290
2025
Q4
$9.9K Sell
610
-123
-17% -$2.01K ﹤0.01% 1997
2025
Q3
$11K Sell
733
-168
-19% -$2.05K ﹤0.01% 1897
2025
Q2
$10.5K Buy
901
+569
+171% +$5.17K ﹤0.01% 1870
2025
Q1
$2.47K Hold
332
– – ﹤0.01% 2241
2024
Q4
$1.99K Buy
+332
New +$1.83K ﹤0.01% 2061
2023
Q4
– Sell
-71
Closed -$387 – 1915
2023
Q3
$387 Sell
71
-236
-77% -$1.56K ﹤0.01% 1742
2023
Q2
$2.06K Buy
+307
New +$2.28K ﹤0.01% 1366

Other funds holding ADPT

Versant Capital Management's ADPT Position: Q3 2026 in Review

Versant Capital Management increased its Adaptive Biotechnologies (ADPT) stake by 8.1% in Q3 2026, buying an estimated $982 and bringing the position to 534 shares worth $15.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2083.

Versant Capital Management first reported a position in ADPT in Q2 2023 and has held it in 10 quarters since. 334 funds tracked by Wall St. Rank hold ADPT as of Q3 2026.

  • Versant Capital Management held 534 shares of Adaptive Biotechnologies worth $15.4K as of Q3 2026.
  • Versant Capital Management bought 40 Adaptive Biotechnologies shares in Q3 2026, an estimated $982.
  • Adaptive Biotechnologies made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2083 holding.
  • Versant Capital Management first reported a position in Adaptive Biotechnologies in Q2 2023 and has held it in 10 quarters since.
  • 334 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.